Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices 21997 

documents filed in connection with this 

investigation are or will be available for 

inspection during official business 

hours (8:45 a.m. to 5:15 p.m.) in the 

Office of the Secretary, U.S. 

International Trade Commission, 500 E 

Street SW., Washington, DC 20436, 

telephone (202) 205–2000. General 

information concerning the Commission 

may also be obtained by accessing its 

Internet server at http://www.usitc.gov. 

The public record for this investigation 

may be viewed on the Commission’s 

electronic docket (EDIS) at http:// 

edis.usitc.gov. Hearing-impaired 

persons are advised that information on 

this matter can be obtained by 

contacting the Commission’s TDD 

terminal on (202) 205–1810. 

SUPPLEMENTARY INFORMATION: The 

Commission instituted this investigation 

on June 21, 2011, based on a complaint 

filed by MOSAID Technologies Inc. of 

Ottawa, Canada (‘‘MOSAID’’), alleging 

violations of section 337 of the Tariff 

Act of 1930, as amended (19 U.S.C. 

1337), in the importation into the 

United States, the sale for importation, 

and the sale within the United States 

after importation of certain equipment 

for communications networks, 

including switches, routers, gateways, 

bridges, wireless access points, cable 

modems, IP phones and products 

containing same by reason of 

infringement of certain claims of U.S. 

Patent Nos. 7,035,280; 7,292,600; 

7,830,858; 6,842,459; 7,633,966; and 

5,841,360. 76 FR 36154–55 (June 21, 

2011). The Notice of Investigation 

named the following as respondents: 

Cisco Systems, Inc. of San Jose, 

California; Cisco Consumer Products 

LLC of Irvine, California; Cisco Systems 

International B.V. of Amsterdam, 

Netherlands; and Scientific Atlanta LLC 

of Lawrenceville, California 

(collectively ‘‘Respondents’’). The Office 

of Unfair Import Investigations was 

named as a party. 

On March 14, 2012, MOSAID and 

Respondents jointly filed to terminate 

the investigation in its entirety based on 

a settlement agreement, which was 

attached to the motion. On March 21, 

2012, the parties supplemented their 

motion to identify additional 

agreements that concern the 

investigation. 

On March 21, 2012, the ALJ issued 

the subject ID granting the joint motion 

to terminate the investigation in its 

entirety pursuant to section 210.21(b) of 

the Commission’s Rules of Practice and 

Procedure (19 CFR 210. 21(b)). No 

petitions for review of the subject ID 

were filed. 

The Commission has determined not 

to review the ID. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended (19 U.S.C. 1337), and in 

section 210.42 of the Commission’s 

Rules of Practice and Procedure (19 CFR 

210.42). 

By order of the Commission. 

Issued: April 9, 2012. 

James R. Holbein, 

Secretary to the Commission. 

[FR Doc. 2012–8851 Filed 4–11–12; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

[OMB Number 1105–NEW] 

Agency Information Collection 

Activities: Proposed Collection; 

Comments Requested: September 11th 

Victim Compensation Fund Objection 

Form 

ACTION: 30-Day Notice of Information 

Collection Under Review. 

The Department of Justice (DOJ), Civil 

Division, September 11th Victim 

Compensation Fund, will be submitting 

the following information collection 

request to the Office of Management and 

Budget (OMB) for review and approval 

in accordance with the Paperwork 

Reduction Act of 1995. The proposed 

information collection is published to 

obtain comments from the public and 

affected agencies. This proposed 

information collection was previously 

published in the Federal Register, 

Volume 77, Number 20, Page 4827 on 

January 31, 2012, allowing for a 60 day 

comment period. 

The purpose of this notice is to allow 

for an additional 30 days for public 

comment until May 14, 2012. This 

process is conducted in accordance with 

5 CFR 1320.10. 

Written comments concerning this 

information collection should be sent to 

the Office of Information and Regulatory 

Affairs, Office of Management and 

Budget, Attn: DOJ Desk Officer. The best 

way to ensure your comments are 

received is to email them to 

oira_submission@omb.eop.gov or fax 

them to 202–395–7285. All comments 

should reference the 8 digit OMB 

number for the collection or the title of 

the collection. If you have questions 

concerning the collection, please call 

Jonathan Olin, 202–514–5585. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address one or more 

of the following four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

—Evaluate the accuracy of the agencies 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

(1) Type of Information Collection: 

New collection. 

(2) Title of the Form/Collection: 

Victim Compensation Objection Form. 

(3) Agency form number, if any, and 

the applicable component of the 

Department of Justice sponsoring the 

collection: Form Number: N/A. Civil 

Division. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: Anyone expressing a 

potential objection to the filing of a 

claim by a purported personal 

representative of a deceased victim. 

Abstract: This form is to be submitted in 

connection with potential objections 

made to claims filed with the September 

11th Victim Compensation Fund of 

2001. The form asks that the objection 

be characterized and explained or be 

withdrawn. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: 50 objectors with an average of 

2.0 hours per response. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: There are an estimated 100 

annual total burden hours associated 

with thiscollection. 

If additional information is required 

contact: Jerri Murray, Department 

Clearance Officer, Policy and Planning 

Staff, Justice Management Division, 

Department of Justice, Two Constitution 

mstockstill on DSK4VPTVN1PROD with NOTICES

21998 Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices 

Square, 145 N Street NE., Room 2E–508, 

Washington, DC 20530. 

Jerri Murray, 

Department Clearance Officer, PRA, U.S. 

Department of Justice. 

[FR Doc. 2012–8398 Filed 4–11–12; 8:45 am] 

BILLING CODE 4410–12–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances: 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on 

December 7, 2011, Meda 

Pharmaceuticals Inc., 705 Eldorado 

Street, Decatur, Illinois 62523, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of Nabilone 

(7379), a basic class of controlled 

substance listed in schedule II. 

The company plans to import the 

listed controlled substance for 

distribution to its customers. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration, 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than May 14, 2012. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

40 FR 43745–46, all applicants for 

registration to import a basic class of 

any controlled substance listed in 

schedule I or II are, and will continue 

to be, required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: April 2, 2012. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2012–8761 Filed 4–11–12; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances, 

Notice of Application, Lipomed, Inc. 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on January 

30, 2012, Lipomed, Inc., One Broadway, 

Cambridge, Massachusetts 02142, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as an importer of the 

following basic classes of controlled 

substances: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

4-methyl-N-methylcathinone 

(1248).

I 

N–Ethylamphetamine (1475) ........ I 

N,N–Dimethylamphetamine 

(1480).

I 

Fenethylline (1503) ....................... I 

Aminorex (1585) ........................... I 

4–Methylaminorex (cis isomer) 

(1590).

I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Methaqualone (2565) ................... I 

Mecloqualone (2572) .................... I 

1–Pentyl-3-(1-naphthoyl)indole 

(7118).

I 

1–Butyl-3-(1-naphthoyl)-indole 

(7173).

I 

1-[2-(4–Morpholinyl)ethyl]-3–1(1- 

naphthoyl) indole (7200).

I 

Alpha-ethyltryptamine (7249) ....... I 

Ibogaine (7260) ............................ I 

5-(1,1–Dimethylheptyl)-2-[(1R,3S)- 

3- 

Drug Schedule 

hydroxycyclohexyl]-phenol (7297) I 

5-(1,1–Dimethyloctyl)-2-[(1R,3S)- 

3- 

hydroxycyclohexyl]-phenol (7298) I 

Lysergic acid diethylamide (7315) I 

2,5–Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Parahexyl (7374) .......................... I 

Nabilone (7379) ............................ I 

Mescaline (7381) .......................... I 

3,4,5–Trimethoxyamphetamine 

(7390).

I 

4–Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4–Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4–Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5–Dimethoxyamphetamine 

(7396).

I 

2,5–Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4–Methylenedioxyamphetamine 

(7400).

I 

5–Methoxy-3,4- 

methylenedioxyamphetamine 

(7401).

I 

N–Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4–Methylenedioxy-Nethylamphetamine (7404).I 

3,4– 

Methylenedioxymethamphetamine (7405).

I 

4–Methoxyamphetamine (7411) ... I 

5–Methoxy-N–Ndimethyltryptamine (7431).I 

Alpha-methyltryptamine (7432) .... I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

5–Methoxy-N,Ndiisopropyltryptamine (7439).I 

N–Ethyl-1-phenylcyclohexylamine 

(7455).

I 

1-(1–Phenylcyclohexyl)pyrrolidine 

(7458).

I 

1-[1-(2– 

Thienyl)cyclohexyl]piperidine 

(7470).

I 

1-[1-(2– 

Thienyl)cyclohexyl]pyrrolidine 

(7473).

I 

N–Ethyl-3-piperidyl benzilate 

(7482).

I 

N–Methyl-3-piperidyl benzilate 

(7484).

I 

N–Benzylpiperazine (7493) .......... I 

3,4-methylenedioxypyrovalerone 

(7535).

I 

3,4-methylenedioxy-Nmethylcathinone (7540).I 

Alphaprodine (9010) ..................... I 

Acetyldihydrocodeine (9051) ........ I 

Benzylmorphine (9052) ................ I 

Codeine-N-oxide (9053) ............... I 

Cyprenorphine (9054) .................. I 

Desomorphine (9055) ................... I 

Etorphine (except HCl) (9056) ..... I 

mstockstill on DSK4VPTVN1PROD with NOTICES